Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
| Conditions: | Mesolthelioma|Esophageal Cancer|Lung Cancer |
| Start Date: | December 1, 2010 |
| Phase: | Phase I |
| Status: | Recruiting |
| NCT ID: | NCT01258868 |
| Study Type: | Interventional |
| Intervention: | Drug: Celecoxib|Drug: ISCOMATRIX (TM) Adjuvant|Biological: Autologous Tumor Cell Vaccine |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | National Cancer Institute (NCI) |
| Ages: | Adult|Senior |
| Enrollment: | 120 |
| Funded By: | NIH |
| First Received: | December 10, 2010 |
| End Date: | December 1, 2017 |
| Last Updated: | January 11, 2011 |
| Last Verified: | November 1, 2010 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
